Biophage signs first client for phage therapy
Biophage Pharma Inc. reported that it has concluded the sales of LISTEX(TM) to a cheese producer in the US. Securing this sale marks the beginning of a business relationship with the first client who intends to develop and use phage therapy as a biological solution to potential Listeria monocytogenes (Listeria) contamination in cheese.
On December 4, 2006, Biophage signed an MOU with EBI Food Safety (TheHague, Netherlands) for the sales and distribution of LISTEX(TM) in North America. LISTEX(TM) is the first bacteriophage product to receive FDA GRAS (Generally Recognized As Safe) recognition for the control of Listeria contaminations in cheese.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.